At the Singer Group, we partner with pharmaceutical companies to study novel new drugs for patients with advanced lung diseases, specifically focusing on cystic fibrosis and bronchiectasis. With Vertex Pharmaceuticals, we were involved in the trials for Trikafta, a novel drug that has revolutionized the treatment of cystic fibrosis. Additionally, we helped with the Simplify trial, which tested if hypertonic saline or dornase alpha were required for maintaining lung function in people with cystic fibrosis. Currently, we're working on a trial for a combination therapy for cystic fibrosis patients.
In the near future, we are hoping to start clinical trials for patients with bronchiectasis, a rare lung disease. We appreciate the kind participation of our patients who are helping improve the treatment of people suffering from these lung diseases.
